Log in

NASDAQ:CRTXCortexyme Stock Price, Forecast & News

$44.39
+0.26 (+0.59 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$43.49
Now: $44.39
$44.68
50-Day Range
$39.85
MA: $45.13
$51.15
52-Week Range
$19.35
Now: $44.39
$73.84
Volume88,365 shs
Average Volume68,273 shs
Market Capitalization$1.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.19 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone415-910-5717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.30 per share

Profitability

Net Income$-36,980,000.00

Miscellaneous

Employees16
Market Cap$1.31 billion
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable
$44.39
+0.26 (+0.59 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 19.9% and is now trading at $44.39.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cortexyme
.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Cortexyme
.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings data on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.16.
View Cortexyme's earnings history
.

What price target have analysts set for CRTX?

3 equities research analysts have issued 12 month price objectives for Cortexyme's shares. Their forecasts range from $59.00 to $76.00. On average, they expect Cortexyme's stock price to reach $68.33 in the next year. This suggests a possible upside of 53.9% from the stock's current price.
View analysts' price targets for Cortexyme
.

Has Cortexyme been receiving favorable news coverage?

Media coverage about CRTX stock has trended positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Cortexyme
.

Are investors shorting Cortexyme?

Cortexyme saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 1,550,000 shares, a decrease of 7.7% from the July 15th total of 1,680,000 shares. Based on an average daily volume of 150,300 shares, the days-to-cover ratio is currently 10.3 days. Currently, 13.0% of the shares of the company are short sold.
View Cortexyme's Short Interest
.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include EPIQ Capital Group LLC (11.36%), Alps Advisors Inc. (0.14%), SG Americas Securities LLC (0.13%), Swiss National Bank (0.11%), UBS Group AG (0.08%) and New York State Common Retirement Fund (0.05%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc.
View institutional ownership trends for Cortexyme
.

Which major investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., UBS Group AG, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Cortexyme
.

Which major investors are buying Cortexyme stock?

CRTX stock was acquired by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, SG Americas Securities LLC, Swiss National Bank, Letko Brosseau & Associates Inc., Virtu Financial LLC, Strs Ohio, Principal Financial Group Inc., and State Board of Administration of Florida Retirement System. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc.
View insider buying and selling activity for Cortexyme
.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $44.39.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.31 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.